Clinical

Our top dermatology content of 2025 highlights AI wearables, new biologics, emerging vitiligo treatments, and strategies for rare and complex skin diseases.

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Sequential BTK and BCL2 inhibitors yield high initial response rates, but durability remains a challenge in the real-world setting for CLL.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

This year's most-watched video evaluated how President Donald Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

Real-world evidence highlights the effectiveness of lisocabtagene maraleucel in treating relapsed or refractory chronic lymphocytic leukemia (R/R CLL).

Our top 5 heart failure content of 2025 include FDA approvals, GDMT optimization, risk markers like LBBB and SDOH, and value-based care models improving outcomes in heart failure.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.

Experts discuss the unmet needs in desmoid tumor management, emphasizing personalized treatment, quality of life, and the importance of specialized care.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.

Experts discuss the challenges of diagnosing rare diseases and the potential role of AI in improving patient management and treatment outcomes.

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted education to ensure earlier therapy and better patient outcomes.

Explore the integration of Desmoid Tumor Working Group recommendations with NCCN guidelines and the importance of shared decision-making in patient care.

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating comprehensive, multidisciplinary supportive care including pulmonary rehabilitation and comorbidity management.

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct strengths and limitations. IV administration offers established dosing precision, flexibility for complex regimens, and familiarity across oncology practices, but it is often associated with longer chair time, higher staffing demands, and increased use of infusion resources. In contrast, SC injections provide a more streamlined approach, with shorter administration times and reduced need for infusion infrastructure. Emerging evidence suggests that SC formulations can meaningfully decrease health care utilization, improve clinic efficiency, and enhance patient convenience without compromising clinical outcomes. For patients, SC delivery may translate into less time in the clinic and a more favorable treatment experience, while practices may benefit from improved throughput and optimized resource allocation. Together, these considerations highlight the growing value of SC formulations in evolving oncology care models.

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, and long-term safety data to reduce costly treatment-resistant depression.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages.

New data suggests dextromethorphan plus bupropion may offer managed care cost containment by increasing remission rates in depression.

Zoe D. Draelos, MD, from Duke University, notes that clascoterone cream's unique sebum reduction mechanism provides effective, highly tolerable, and core acne treatment.

The FDA approved subcutaneous mosunetuzumab for relapsed follicular lymphoma, providing a more convenient outpatient option.

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.